Benitec Biopharma (BNTC) Receivables (2019 - 2025)

Benitec Biopharma (BNTC) posted Receivables of $130000.0 for Q4 2025, up 1757.14% sequentially from $7000.0 in Q3 2025.

Benitec Biopharma (BNTC) Receivables (2019 - 2025) Analysis & Trends

Benitec Biopharma has reported Receivables for 7 years, with the latest figure at $130000.0 in Q4 2025.

Quarterly Receivables changed N/A year-over-year to $130000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $130000.0 (changed N/A YoY) and the FY2025 annual result came in at $33000.0, down 85.59% from the prior year.
Receivables grew to $130000.0 in Q4 2025 per BNTC's latest filing, from $7000.0 in the prior quarter.
Over five years, Receivables peaked at $229000.0 in Q2 2024 and troughed at $3000.0 in Q3 2021.
A 5-year average of $42000.0 and a median of $25000.0 in 2021 frame the typical range for Receivables.
The sharpest annual moves came in 2023 and 2025: Receivables jumped 1733.33% in 2023, then slumped 94.34% in 2025.
Over 5 years, Receivables stood at $5000.0 in 2021, then surged by 1260.0% to $68000.0 in 2022, then slipped by 22.06% to $53000.0 in 2023, then tumbled by 92.45% to $4000.0 in 2024, then surged by 3150.0% to $130000.0 in 2025.
According to Business Quant data, Receivables over the past three periods registered $130000.0, $7000.0, and $33000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.93 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.06 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	1.84 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	912.74 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	215.33 Mn
10	Benitec Biopharma	577.39 Mn	388.49 Mn	-	130,000.00

Download Data